• XTR006, an ¹⁸F-labeled PET imaging agent with a high-affinity to Tau protein developed for Alzheimer’s disease, received clinical approval.
• The New Drug Application of Florbetaben F 18 injection was being accepted.
• The first subject had been dosed in the Phase III clinical trial of lutetium Lu 177 dotatate, which is the first domestic targeted therapeutic radiopharmaceutical independently developed by Sinotau, on Sept.24, 2022.
• Clinical trial application of [¹⁷⁷Lu]Lu-XT033 injection was approved.
• The single-photon emission computed tomography(SPECT) machine received registration certificate for medical device, becoming the first large professional equipment in the field of Chinese cardiac nuclear medicine to promote domestic production.